{"schema_version":"secwatch.filing_event.v1","accession":"0001185185-23-000691","form_type":"8-K","ticker":"IGC","cik":"0001326205","company_name":"IGC Pharma, Inc.","filed_at":"2023-07-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.583206+00:00","generated_at":"2026-06-13T10:56:04.071949+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"IGC Pharma secures $12M revolving credit from O-Bank for Alzheimer's research","bullets":["Up to $12M revolving credit facility; initial 12-month term with possible extension.","Draws limited to $1M per 30-day period; interest rate is 1% plus certificate of deposit rate.","Bradbury Asset Management has collateralized cash assets supporting the line; Bradbury recently invested $3M in IGC.","Proceeds support working capital, primarily for Phase 2 trial of IGC-AD1 for Alzheimer's agitation.","Phase 2 trial targets 146 patients; 16 completed; 8 sites secured; targeting completion in Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-23-000691","json":"https://secwatch.observer/filing/0001185185-23-000691.json","markdown":"https://secwatch.observer/filing/0001185185-23-000691.md","text":"https://secwatch.observer/filing/0001185185-23-000691.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326205/000118518523000691/0001185185-23-000691-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326205/000118518523000691/igcpharma20230706c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:56:04.071949+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7ed3a2c93de0b000a40024148464cdfb49120769","claim":"IGC Pharma, Inc. incurred credit facility of up to USD$12,000,000.00 with O-Bank, CO., LTD. at interest rate mentioned in the Certificate of Deposit, as the case may be, plus maturing first anniversary of the Effective Date.","evidence_excerpt":"On June 30, 2023, (the “Effective Date”), IGC Pharma, Inc. (“IGC” or “Borrower”) entered into a Master Loan and Security Agreement along with the General Banking Facility Letter (collectively called the “Loan Agreement”) with O-Bank, CO., LTD., a banking corporation incorporated under the laws of Taiwan, as administrative agent and lender (the “Lender’) pursuant to which the Borrower may borrow up to USD$12,000,000.00 only or the equivalent thereof in other major currencies (the “Credit Facility”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518523000691/0001185185-23-000691-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"up to USD$12,000,000.00"},{"label":"Counterparty","value":"O-Bank, CO., LTD."},{"label":"Rate","value":"interest rate mentioned in the Certificate of Deposit, as the case may be, plus"},{"label":"Maturity","value":"first anniversary of the Effective Date"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"ea6c0d0928dc3f99e2cc7d24b0d286ffe3a1663f","claim":"IGC Pharma, Inc. entered into Loan Agreement with O-Bank, CO., LTD. valued at up to USD$12,000,000.00 (effective 2023-06-30).","evidence_excerpt":"On June 30, 2023, (the “Effective Date”), IGC Pharma, Inc. (“IGC” or “Borrower”) entered into a Master Loan and Security Agreement along with the General Banking Facility Letter (collectively called the “Loan Agreement”) with O-Bank, CO., LTD., a banking corporation incorporated under the laws of Taiwan, as administrative agent and lender (the “Lender’) pursuant to which the Borrower may borrow up to USD$12,000,000.00 only or the equivalent thereof in other major currencies (the “Credit Facility”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518523000691/0001185185-23-000691-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"O-Bank, CO., LTD."},{"label":"Value","value":"up to USD$12,000,000.00"},{"label":"Effective","value":"2023-06-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}